FR2914633A1 - Gaseous mixture useful to prepare inhalable drug to prevent or reduce post-operative hyperalgesia induced by opioid in human, comprises oxygen and xenon - Google Patents

Gaseous mixture useful to prepare inhalable drug to prevent or reduce post-operative hyperalgesia induced by opioid in human, comprises oxygen and xenon Download PDF

Info

Publication number
FR2914633A1
FR2914633A1 FR0754342A FR0754342A FR2914633A1 FR 2914633 A1 FR2914633 A1 FR 2914633A1 FR 0754342 A FR0754342 A FR 0754342A FR 0754342 A FR0754342 A FR 0754342A FR 2914633 A1 FR2914633 A1 FR 2914633A1
Authority
FR
France
Prior art keywords
xenon
gaseous mixture
oxygen
opioid
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR0754342A
Other languages
French (fr)
Inventor
Thomas Marx
Gabriela Apiou
Vincent Lagente
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Air Liquide SA
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Original Assignee
Air Liquide SA
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Air Liquide SA, LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude filed Critical Air Liquide SA
Priority to FR0754342A priority Critical patent/FR2914633A1/en
Publication of FR2914633A1 publication Critical patent/FR2914633A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics

Abstract

Gaseous mixture comprises oxygen (2-10 vol.%) and xenon.

Description

La présente invention porte sur un mélange gazeux contenant de l'oxygèneThe present invention relates to a gaseous mixture containing oxygen

(02) et du xénon (Xe) destiné à prévenir ou à minimiser les hyperalgésies post-opératoires chez l'homme. Durant les anesthésies générales, il est habituel d'administrer des hypnotiques volatiles ou intraveineux aux patients, ou des substances analgésiques intraveineuses ou opioïdes.  (02) and Xenon (Xe) for preventing or minimizing postoperative hyperalgesia in humans. During general anesthesia, it is usual to administer volatile or intravenous hypnotics to patients, or intravenous or opioid analgesic substances.

Par exemple, on peut citer les produits anesthésiques suivants qui sont couramment utilisés en anesthésie, tels que sevoflurane, desflurane, fentanyl, remifentamyl ou autres opioïdes... Or, il a été constaté en pratique que cela induit des effets indésirables appelés hyperalgésie post-opératoire , qui se traduisent par une sensibilité à la douleur des patients d'intensité accrue après l'opération ou la phase de diagnostic durant laquelle le patient a été anesthésié, qu'avant celle-ci. Cette hyperalgésie post-opératoire engendre donc une plus grande sensibilité à la douleur quelle qu'en soit l'origine ou la localisation, c'est-à-dire qu'elle soit localisée ou non dans la zone traitée durant l'opération ou la phase de diagnostic ou non.  For example, there may be mentioned the following anesthetic products which are commonly used in anesthesia, such as sevoflurane, desflurane, fentanyl, remifentamyl or other opioids ... However, it has been found in practice that this induces undesirable effects called post-hyperalgesia. which result in increased pain sensitivity of the patients after the operation or the diagnosis phase during which the patient was anesthetized, than before this. This postoperative hyperalgesia therefore gives rise to greater sensitivity to pain irrespective of the origin or location, ie whether or not it is located in the treated area during the operation or the diagnosis phase or not.

Cet effet est notable durant une période longue, pouvant aller notamment jusqu'à 1 an, et conduit donc à une diminution de la qualité de vie des patients puisque ceux-ci seront plus sensibles à la douleur durant tout ce temps. Un but de l'invention est de permettre d'éviter ou de freiner ou diminuer l'apparition de ce phénomène néfaste d'hyperalgésie post-opératoire chez les patients.  This effect is noticeable for a long period, including up to 1 year, and therefore leads to a decrease in the quality of life of patients since they will be more sensitive to pain during all this time. An object of the invention is to prevent or slow or reduce the occurrence of this harmful phenomenon of postoperative hyperalgesia in patients.

La solution de l'invention est alors un mélange gazeux contenant de l'oxygène (02) et du xénon (Xe) destiné à prévenir ou à minimiser une hyperalgésie post-opératoires chez l'homme, caractérisé en ce que la proportion de xénon est comprise entre 2 et 10 % en volume. Selon le cas, le mélange gazeux de l'invention peut comprendre l'une ou plusieurs des caractéristiques suivantes : - il contient, en outre, de l'oxygène ou de l'oxygène et de l'azote. - il est constitué uniquement d'oxygène et de xénon. - il est constitué uniquement d'oxygène, d'azote et de xénon, la proportion volumique en oxygène étant comprise entre 15 et 25%. - il contient de préférence de 3 à 9 % de xénon environ. - il est conditionné sous une pression supérieure à 2 bar au sein d'un récipient sous pression, en particulier à plus de 100 bar dans une bouteille de gaz. En d'autres termes, le mélange gazeux contenant de l'oxygène et du xénon selon 5 l'invention est utilisable en tant que médicament inhalable destiné à prévenir une hyperalgésie chez l'homme. Dit autrement encore, l'invention porte aussi sur l'utilisation d'un mélange gazeux selon l'invention pour fabriquer un médicament destiné à prévenir ou à diminuer une hyperalgésie chez l'homme, en particulier lorsque l'hyperalgésie est de type postopératoire, en particulier induite par au moins un opioïde. Le mélange gazeux de l'invention est administré par inhalation au patient, par exemple avec un masque alimenté en gaz ou au moyen d'un ventilateur respiratoire, et cette administration se fait durant la phase d'anesthésie dudit patient. L'invention porte donc aussi sur une méthode d'anesthésie d'un patient comprenant 15 les étapes de : a) administrer à un patient une substance anesthésique ou analgésique opioïde de manière à obtenir une anesthésie dudit patient par ladite substance, b) maintenir le patient sous-anesthésie durant une durée donnée, en particulier durant au moins une partie de la phase diagnostic et/ou la phase opératoire dudit 20 patient, c) administrer audit patient, avant, durant et/ou après l'étape b), un mélange gazeux d'oxygène et de xénon selon l'invention. Grâce au mélange gazeux de l'invention, on peut lutter efficacement contre l'effet néfaste d'hyperalgésie post-opératoire. 25 30  The solution of the invention is then a gaseous mixture containing oxygen (02) and xenon (Xe) intended to prevent or minimize postoperative hyperalgesia in humans, characterized in that the proportion of xenon is between 2 and 10% by volume. Depending on the case, the gaseous mixture of the invention may comprise one or more of the following characteristics: it further contains oxygen or oxygen and nitrogen. it consists solely of oxygen and xenon. it consists solely of oxygen, nitrogen and xenon, the volume proportion of oxygen being between 15 and 25%. it preferably contains from 3 to 9% of xenon approximately. - It is conditioned under a pressure greater than 2 bar in a pressure vessel, in particular more than 100 bar in a gas cylinder. In other words, the gaseous mixture containing oxygen and xenon according to the invention is usable as an inhalable medicament for preventing hyperalgesia in humans. In other words, the invention also relates to the use of a gaseous mixture according to the invention for the manufacture of a medicament for preventing or reducing hyperalgesia in humans, in particular when the hyperalgesia is of the postoperative type, in particular induced by at least one opioid. The gaseous mixture of the invention is administered by inhalation to the patient, for example with a mask fed with gas or by means of a respiratory ventilator, and this administration is done during the anesthesia phase of said patient. The invention thus also relates to a method of anesthesia of a patient comprising the steps of: a) administering to a patient an opioid anesthetic or analgesic substance so as to obtain anesthesia of said patient by said substance, b) maintaining the under-anesthesia during a given period, in particular during at least part of the diagnostic phase and / or the operating phase of said patient; c) administering to said patient, before, during and / or after step b), a gaseous mixture of oxygen and xenon according to the invention. Thanks to the gaseous mixture of the invention, the harmful effect of postoperative hyperalgesia can be effectively counteracted. 25 30

Claims (9)

Revendicationsclaims 1. Mélange gazeux contenant de l'oxygène (02) et du xénon (Xe), caractérisé en ce que la proportion de xénon est comprise entre 2 et 10 % en volume.  1. Gaseous mixture containing oxygen (02) and xenon (Xe), characterized in that the proportion of xenon is between 2 and 10% by volume. 2. Mélange gazeux selon la revendication 1, caractérisé en ce qu'il contient, en outre, de l'oxygène ou de l'oxygène et de l'azote.  2. gas mixture according to claim 1, characterized in that it further contains oxygen or oxygen and nitrogen. 3. Mélange gazeux selon l'une des revendications 1 ou 2, caractérisé en ce 10 qu'il est constitué uniquement d'oxygène et de xénon.  3. Gas mixture according to one of claims 1 or 2, characterized in that it consists solely of oxygen and xenon. 4. Mélange gazeux selon l'une des revendications 1 ou 2, caractérisé en ce qu'il est constitué uniquement d'oxygène, d'azote et de xénon, la proportion volumique en oxygène étant comprise entre 15 et 25%.  4. Gaseous mixture according to one of claims 1 or 2, characterized in that it consists solely of oxygen, nitrogen and xenon, the volume proportion of oxygen is between 15 and 25%. 5. Mélange gazeux selon l'une des revendications 1 à 4, caractérisé en ce qu'il contient de préférence de 3 à 9% de xénon.  5. Gas mixture according to one of claims 1 to 4, characterized in that it preferably contains 3 to 9% xenon. 6. Mélange gazeux selon l'une des revendications 1 à 4, caractérisé en ce qu'il 20 est conditionné sous une pression supérieure à 2 bar au sein d'un récipient sous pression, en particulier à plus de 100 bar dans une bouteille de gaz.  6. Gaseous mixture according to one of claims 1 to 4, characterized in that it is conditioned under a pressure greater than 2 bar in a pressure vessel, in particular more than 100 bar in a bottle of gas. 7. Mélange gazeux contenant de l'oxygène et du xénon selon l'une des revendications 1 à 6 en tant que médicament inhalable destiné à prévenir une hyperalgésie 25 chez l'homme.  7. A gas mixture containing oxygen and xenon according to one of claims 1 to 6 as an inhalable medicament for preventing hyperalgesia in humans. 8. Utilisation d'un mélange gazeux selon l'une des revendications 1 à 7 pour fabriquer un médicament destiné à prévenir ou à diminuer une hyperalgésie chez l'homme. 30  8. Use of a gas mixture according to one of claims 1 to 7 for manufacturing a medicament for preventing or reducing hyperalgesia in humans. 30 9. Utilisation selon la revendication 8, dans laquelle l'hyperalgésie est de type post-opératoire, en particulier elle est induite par au moins un opioïde. 15  9. Use according to claim 8, wherein the hyperalgesia is of the post-operative type, in particular it is induced by at least one opioid. 15
FR0754342A 2007-04-06 2007-04-06 Gaseous mixture useful to prepare inhalable drug to prevent or reduce post-operative hyperalgesia induced by opioid in human, comprises oxygen and xenon Withdrawn FR2914633A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0754342A FR2914633A1 (en) 2007-04-06 2007-04-06 Gaseous mixture useful to prepare inhalable drug to prevent or reduce post-operative hyperalgesia induced by opioid in human, comprises oxygen and xenon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0754342A FR2914633A1 (en) 2007-04-06 2007-04-06 Gaseous mixture useful to prepare inhalable drug to prevent or reduce post-operative hyperalgesia induced by opioid in human, comprises oxygen and xenon

Publications (1)

Publication Number Publication Date
FR2914633A1 true FR2914633A1 (en) 2008-10-10

Family

ID=38577490

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0754342A Withdrawn FR2914633A1 (en) 2007-04-06 2007-04-06 Gaseous mixture useful to prepare inhalable drug to prevent or reduce post-operative hyperalgesia induced by opioid in human, comprises oxygen and xenon

Country Status (1)

Country Link
FR (1) FR2914633A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011015428A1 (en) 2009-08-04 2011-02-10 L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Use of xenon for treating hypersensitivity to pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10328272A1 (en) * 2002-06-22 2004-01-15 Messer Griesheim Gmbh Inhalable spasmolytic agent, useful for e.g. treating vasospasms or cerebral blood flow disorders, comprises xenon or gas mixture containing xenon
DE10336768A1 (en) * 2002-08-10 2004-02-26 Messer Griesheim Gmbh Medicament for improving oxygen utilization in the body, useful e.g. in combating ischemia or reperfusion damage, comprising xenon, optionally together with oxygen or nitrogen monoxide source
FR2858233A1 (en) * 2003-07-30 2005-02-04 Air Liquide Sante Int INHALABLE GAS MEDICINE BASED ON XENON AND NITROGEN PROTOXIDE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10328272A1 (en) * 2002-06-22 2004-01-15 Messer Griesheim Gmbh Inhalable spasmolytic agent, useful for e.g. treating vasospasms or cerebral blood flow disorders, comprises xenon or gas mixture containing xenon
DE10336768A1 (en) * 2002-08-10 2004-02-26 Messer Griesheim Gmbh Medicament for improving oxygen utilization in the body, useful e.g. in combating ischemia or reperfusion damage, comprising xenon, optionally together with oxygen or nitrogen monoxide source
FR2858233A1 (en) * 2003-07-30 2005-02-04 Air Liquide Sante Int INHALABLE GAS MEDICINE BASED ON XENON AND NITROGEN PROTOXIDE

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011015428A1 (en) 2009-08-04 2011-02-10 L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Use of xenon for treating hypersensitivity to pain
FR2948878A1 (en) * 2009-08-04 2011-02-11 Air Liquide USE OF XENON TO TREAT PAIN HYPERSENSITIVITY
US20120128789A1 (en) * 2009-08-04 2012-05-24 Universite Bordeau Segalen Use of xenon for treating hypersensitivity to pain
US8632821B2 (en) * 2009-08-04 2014-01-21 L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude Use of xenon for treating hypersensitivity to pain

Similar Documents

Publication Publication Date Title
US10792265B2 (en) Methods of treating or preventing fibrotic lung diseases
Kulka et al. Clonidine prevents sevoflurane-induced agitation in children
O'Connor et al. Inhibition of nociception-induced spinal sensitization by anesthetic agents
Nagele et al. Exploring nitrous oxide as treatment of mood disorders: basic concepts
Chang et al. Effect of endotracheal tube cuff shape on postoperative sore throat after endotracheal intubation
Hanouz et al. Comparison of pre-oxygenation using spontaneous breathing through face mask and high-flow nasal oxygen: A randomised controlled crossover study in healthy volunteers
Rani et al. Rapid and reliable smooth extubation–Comparison of fentanyl with dexmedetomidine: A randomized, double-blind clinical trial
Rasmussen et al. Comparison of xenon with propofol for supplementary general anaesthesia for knee replacement: a randomized study
Guenther et al. Repinotan, a selective 5-HT1A-R-agonist, antagonizes morphine-induced ventilatory depression in anesthetized rats
FR2914632A1 (en) GAS MIXTURE BASED ON O2 OF N2O FOR PREVENTING OR REDUCING HYPERALGESIA
Farhang et al. The effect of zinc lozenge on postoperative sore throat: a prospective randomized, double-blinded, placebo-controlled study
FR2914633A1 (en) Gaseous mixture useful to prepare inhalable drug to prevent or reduce post-operative hyperalgesia induced by opioid in human, comprises oxygen and xenon
Feng et al. Comparison of the level of free hexafluoro-isopropanol in adults’ blood and the incidence of emergence agitation after anesthesia with different concentrations of sevoflurane in laparoscopic gastrointestinal surgery: a randomized controlled clinical trial
US7235264B2 (en) Cerebral protection with a gas comprising xenon
Lee et al. Preoperatively administered ramosetron oral disintegrating tablets for preventing nausea and vomiting associated with patient-controlled analgesia in breast cancer patients
Wiederkehr et al. Clinical randomized comparison of medetomidine and xylazine for isoflurane balanced anesthesia in horses
Behrends et al. Acute lung injury after peppermint oil injection
Röhm et al. Insignificant effect of desflurane–fentanyl–thiopental on hepatocellular integrity–a comparison with total intravenous anaesthesia using propofol–remifentanil
WO2011154630A1 (en) Krypton-based inhalable gaseous medicinal product for combatting deficiencies or failure of peripheral organs
Tonner et al. Total intravenous or balanced anaesthesia in ambulatory surgery?
Rajan et al. Effect of intracuff dexamethasone on incidence and severity of post operative sore-Prospective randomized study
EP2461816B1 (en) Use of xenon for treating hypersensitivity to pain
Ahmad et al. “Jaws of steel” after very low dose of fentanyl during prebronchoscopy sedation
Hussein Fahmy Kahla et al. The efficacy of magnesium sulphate on emergence agitation in adults following nasal surgeries
EP3733193B1 (en) Inhalable gaseous mixture for treating chronic pain in patients receiving drugs from a plurality of therapeutic classes

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20091231